It is of note that such highly individualized efficacy of PD-1 or PD-L1 blockage is consistent with findings in patients with cancer and infections with other viruses (Nakamoto et al., 2009; Gardiner et al., 2013; Kowanetz et al., 2018; McLane et al., 2019). This evidence concerns the gene CD274 and infection.